sensipar(cinacalcet)盐酸西那卡塞片中文说明（Sensipar (cinacalcet) of cinacalcet tablets that Chinese）.docVIP

下载本文档

133
0
约5.91千字
约 5页
2017-08-20 发布于河南
举报
版权申诉

sensipar(cinacalcet)盐酸西那卡塞片中文说明（Sensipar (cinacalcet) of cinacalcet tablets that Chinese）.doc

1、本文档共5页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

sensipar(cinacalcet)盐酸西那卡塞片中文说明（Sensipar (cinacalcet) of cinacalcet tablets that Chinese）

sensipar(cinacalcet)盐酸西那卡塞片中文说明（Sensipar (cinacalcet) of cinacalcet tablets that Chinese） English Name: Sensipar (Cinacalcet) Chinese drug name: cinacalcet hydrochloride tablets [pharmacological effects] Secondary hyperparathyroidism in chronic kidney disease (CKD) is a progressive disease of calcium and phosphorus metabolism caused by elevated levels of parathyroid hormone (PTH). Elevated PTH stimulated osteoclastic activity and caused resorption of bone. Secondary hyperparathyroidism is designed to reduce PTH and blood calcium, blood phosphorus, and prevent bone disease and systemic effects due to mineral metabolism disorders. The calcium sensing receptor located on the main cell of the parathyroid gland is the major regulator of PTH secretion, which can increase the sensitivity of calcium sensing receptors to extracellular calcium and lower PTH levels, thereby reducing plasma calcium concentration. [pharmacokinetics] This product is 2 ~ 6h after oral blood concentration reached the peak (Cmax), and high fat food and clothes, the area under the curve of the product Cmax and medicine (AUC) increased by 82% and 68% respectively; and a low fat diet with the service, the product of the peak concentration of Cmax and AUC increased 65% and 50% respectively. After the absorption of this product, the concentration of serum was biphasic eliminated, and the half-life was 30 ~ 40h. 7 days after continuous administration, the serum concentration reached steady state, and Cmax and AUC increased proportionally with the increase of dosage. The apparent volume of distribution is 1000L, indicating that the product is widely distributed. The product is combined with plasma protein 93% ~ 97%. This product is a variety of enzymes metabolism, mainly CYP3A4, CYP2D6, CYPlA2. Mainly excreted by the kidneys, accounting for 80% of the dose, and about 15% excreted by faeces. The AUC in patients with moderate and severe hepatic insufficiency increased by 2.4 and 4.2 times, with a half-life o